source
- Lilly to invest extra $4.5B across Indiana manufacturingThe Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.BioPharma Dive · 3mo ago↗ source
- FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from ...Endpoints · 3mo ago↗ source
- FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extendedPierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.